Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Martel Eye Medical Group
mi
from
Rancho Cordova, CA
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Martel Eye Medical Group
mi
from
Rancho Cordova, CA
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
North Valley Eye Medical Group, Inc.
mi
from
Mission Hills, CA
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
North Valley Eye Medical Group, Inc.
mi
from
Mission Hills, CA
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Price Vision Group
mi
from
Indianapolis, IN
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Price Vision Group
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Total Eye Care, PA
mi
from
Memphis, TN
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Total Eye Care, PA
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Whitsett Vision Group
mi
from
Houston, TX
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Whitsett Vision Group
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Comprehensive Eye Care, Ltd/Vision Research Institute, LLC
mi
from
Washington, MO
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Comprehensive Eye Care, Ltd/Vision Research Institute, LLC
mi
from
Washington, MO
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
South Shore Eye Center, LLP
mi
from
Wantagh, NY
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
South Shore Eye Center, LLP
mi
from
Wantagh, NY
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Abrams Eye Center
mi
from
Cleveland, OH
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Abrams Eye Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Ophthalmology Associates
mi
from
Saint Louis, MO
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Ophthalmology Associates
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Bevacizumab Against Recurrent Retinal Detachment
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin
mi
from
Madison, WI
Bevacizumab Against Recurrent Retinal Detachment
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism
A Randomized Placebo-controlled Trial to Investigate the Effect of Lutein and Zeaxanthin Supplementation on Macular Pigment and Visual Function in Albinism - LUtein for VIsion in Albinism (LUVIA)
Status: Enrolling
Updated:  12/31/1969
Wilmer Eye Institute
mi
from
Baltimore, MD
The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism
A Randomized Placebo-controlled Trial to Investigate the Effect of Lutein and Zeaxanthin Supplementation on Macular Pigment and Visual Function in Albinism - LUtein for VIsion in Albinism (LUVIA)
Status: Enrolling
Updated: 12/31/1969
Wilmer Eye Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Study to Assess Loteprednol Etabonate Ophthalmic Gel, 0.38% Versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Status: Enrolling
Updated:  12/31/1969
Bausch & Lomb Incorporated
mi
from
Bridgewater, NJ
Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Study to Assess Loteprednol Etabonate Ophthalmic Gel, 0.38% Versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Status: Enrolling
Updated: 12/31/1969
Bausch & Lomb Incorporated
mi
from
Bridgewater, NJ
Click here to add this to my saved trials
Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
A Randomized, Active-Controlled, Phase II Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation in Subjects With Radiation Retinopathy (RRR Study).
Status: Enrolling
Updated:  12/31/1969
Texas Retina Associates
mi
from
Dallas, TX
Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
A Randomized, Active-Controlled, Phase II Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation in Subjects With Radiation Retinopathy (RRR Study).
Status: Enrolling
Updated: 12/31/1969
Texas Retina Associates
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
A Randomized, Active-Controlled, Phase II Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation in Subjects With Radiation Retinopathy (RRR Study).
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Houston/The Medical Center
mi
from
Houston, TX
Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
A Randomized, Active-Controlled, Phase II Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation in Subjects With Radiation Retinopathy (RRR Study).
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Houston/The Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
A Randomized, Active-Controlled, Phase II Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation in Subjects With Radiation Retinopathy (RRR Study).
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Houston
mi
from
The Woodlands, TX
Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
A Randomized, Active-Controlled, Phase II Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation in Subjects With Radiation Retinopathy (RRR Study).
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Houston
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
A Randomized, Active-Controlled, Phase II Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation in Subjects With Radiation Retinopathy (RRR Study).
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Houston
mi
from
Katy, TX
Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
A Randomized, Active-Controlled, Phase II Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation in Subjects With Radiation Retinopathy (RRR Study).
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Houston
mi
from
Katy, TX
Click here to add this to my saved trials
Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198
An Investigation of Retinal Findings in Patients With Signs and Symptoms of Alzheimer's Disease Enrolled in 09-M-0198
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198
An Investigation of Retinal Findings in Patients With Signs and Symptoms of Alzheimer's Disease Enrolled in 09-M-0198
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retinal Consultants of AZ
mi
from
Phoenix, AZ
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retinal Consultants of AZ
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina Centers, P.C.
mi
from
Tucson, AZ
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina Centers, P.C.
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Northern California Retina Vitreous Associates
mi
from
Mountain View, CA
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Northern California Retina Vitreous Associates
mi
from
Mountain View, CA
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
East Bay Retina Consultants, Inc.
mi
from
Oakland, CA
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
East Bay Retina Consultants, Inc.
mi
from
Oakland, CA
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Southern California Desert Retina Consultants
mi
from
Palm Desert, CA
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Southern California Desert Retina Consultants
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retinal Consultants Medical Group, Inc.
mi
from
Sacramento, CA
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retinal Consultants Medical Group, Inc.
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
University of California, Davis Medical Center
mi
from
Sacramento, CA
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
New England Retina Associates
mi
from
New London, CT
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
New England Retina Associates
mi
from
New London, CT
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
National Ophthalmic Research Institute
mi
from
Fort Myers, FL
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
National Ophthalmic Research Institute
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
University of Florida, Dept of Ophthalmology
mi
from
Jacksonville, FL
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
University of Florida, Dept of Ophthalmology
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Florida Retina Consultants
mi
from
Lakeland, FL
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Florida Retina Consultants
mi
from
Lakeland, FL
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Sarasota Retina Institute
mi
from
Sarasota, FL
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Sarasota Retina Institute
mi
from
Sarasota, FL
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Center for Retina and Macular Disease
mi
from
Winter Haven, FL
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Center for Retina and Macular Disease
mi
from
Winter Haven, FL
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Florida Retina Consultants
mi
from
Winter Haven, FL
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Florida Retina Consultants
mi
from
Winter Haven, FL
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Emory University Eye Center
mi
from
Atlanta, GA
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Emory University Eye Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Southeast Retina Center, P.C.
mi
from
Augusta, GA
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Southeast Retina Center, P.C.
mi
from
Augusta, GA
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Georgia Retina, P.C.
mi
from
Marietta, GA
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Georgia Retina, P.C.
mi
from
Marietta, GA
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Illinois Eye and Ear Infirmary UIC Dept. of Ophthalmology
mi
from
Chicago, IL
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Illinois Eye and Ear Infirmary UIC Dept. of Ophthalmology
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Thomas A. Ciulla, MD, PC
mi
from
Indianapolis, IN
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Thomas A. Ciulla, MD, PC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Sabates Eye Centers
mi
from
Leawood, KA
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Sabates Eye Centers
mi
from
Leawood, KA
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina Associates of Kentucky
mi
from
Lexington, KY
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina Associates of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
University of Kentucky
mi
from
Lexington, KY
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Paducah Retinal Center
mi
from
Paducah, KY
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Paducah Retinal Center
mi
from
Paducah, KY
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Elman Retina Group, PA
mi
from
Baltimore, MD
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Elman Retina Group, PA
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Retina Group of Washington
mi
from
Chevy Chase, MD
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Retina Group of Washington
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Elman Retina Group, P.A.
mi
from
Glen Burnie, MD
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Elman Retina Group, P.A.
mi
from
Glen Burnie, MD
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Cumberland Valley Retina Consultants
mi
from
Hagerstown, MD
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Cumberland Valley Retina Consultants
mi
from
Hagerstown, MD
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
Elman Retina Group, P.A.
mi
from
Pikesville, MD
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
Elman Retina Group, P.A.
mi
from
Pikesville, MD
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
TLC Eyecare and Laser Centers
mi
from
Jackson, MI
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
TLC Eyecare and Laser Centers
mi
from
Jackson, MI
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
VitreoRetinal Surgery
mi
from
Minneapolis, MN
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
VitreoRetinal Surgery
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
The Retina Institute
mi
from
Saint Louis, MO
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
The Retina Institute
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated:  12/31/1969
UNMC Truhlsen Eye Institute
mi
from
Omaha, NE
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Status: Enrolling
Updated: 12/31/1969
UNMC Truhlsen Eye Institute
mi
from
Omaha, NE
Click here to add this to my saved trials